The U.S. Supreme Court on Monday temporarily restored nationwide access to the abortion medication mifepristone by mail, blocking a recent lower-court order that required in-person prescriptions. The one-sentence administrative stay, issued by Justice Samuel Alito, pauses a ruling from the conservative Fifth Circuit Court of Appeals that had reinstated FDA rules mandating that patients obtain mifepristone in person rather than via telemedicine. The stay remains in effect until at least May 11, pending further reviews from the full Court after briefs are submitted by Thursday.

The legal dispute originates from a lawsuit filed by the state of Louisiana, which challenged the FDA’s approval of mail-order access to mifepristone, arguing that this circumvented its near-total abortion ban enacted after the Supreme Court overturned Roe v. Wade in 2022. Louisiana officials contend that the availability of the medication by mail has allowed women in the state to access abortion pills contrary to the ban. They also assert that the policy increase Medicaid costs due to potential complications, and they question the safety of remote prescribing.

In contrast, manufacturers of mifepristone—Danco Laboratories and GenBioPro—argue that the lower court’s ruling causes confusion during critical medical decision-making and is unsupported by scientific evidence. Major medical organizations and reproductive rights advocates point to extensive research affirming mifepristone’s safety and efficacy when prescribed remotely. These advocates emphasize that medication abortion, typically involving mifepristone followed by misoprostol, is now the predominant method used, representing nearly two-thirds of abortions nationally.

Previously, the FDA allowed the remote prescription and mailing of mifepristone starting in 2021, lifting a requirement for in-person dispensing that had been in place since the drug’s 2000 approval. The Fifth Circuit’s Friday decision reinstated the in-person requirement, asserting that the FDA had not sufficiently studied the safety of telehealth prescriptions. The ruling also temporarily prohibited mail distribution of mifepristone across the country, affecting states with and without abortion bans.

The Biden administration, through the FDA and the Department of Health and Human Services, is conducting a review of mifepristone’s safety but requested that litigation be paused pending those findings. Conservative judges on the Fifth Circuit rejected this request, citing concerns over potential "irreparable harm" to patients if mail-order prescriptions continued.

The Supreme Court’s temporary ruling does not indicate how the full Court will ultimately decide the case but provides an interim reprieve for patients and providers relying on telehealth. Justice Alito, who handled this emergency application due to his regional responsibilities, has set a prompt briefing schedule, signaling a possible expedited review.

The case highlights a broader conflict between state abortion restrictions and federal drug regulations, as well as political tensions surrounding abortion access in the run-up to the 2026 midterm elections. While states like Louisiana pursue stricter limitations, many Democratic-led states have enacted laws protecting telehealth provision of abortion pills. Meanwhile, advocates note that even in states with bans—such as Texas—access to abortion pills continues through telemedicine, alternative regimens like misoprostol alone, out-of-state travel for procedures, and underground networks.

As the legal battle unfolds, stakeholders emphasize the complex and evolving nature of abortion access in the United States, underscoring both the political and medical dimensions of ongoing challenges to the distribution of mifepristone.